CTOs on the Move

ABIGO MEDICAL AB

www.abigo.com

 
ABIGO MEDICAL AB is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.abigo.com
  • 1601 K St NW
    Washington, DC USA 20006
  • Phone: 202.778.9428

Executives

Name Title Contact Details

Similar Companies

Covidien

Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Covidien is part of the local fabric of the communities in which we operate around the world. Our success is made possible through the dedication of our 43,000 employees, nearly two-thirds of whom work in 51 manufacturing facilities located in 18 countries. Every day, over 5,500 Covidien sales representatives meet the needs of our customers in 70 countries. In all, our Company derives 45% of its sales from outside the United States. Covidien, formerly Tyco Healthcare, is a medical equipment and supply company, incorporated in Dublin, Ireland, although its corporate offices are located in Mansfield, Massachusetts, USA. On June 29, 2007, Covidien became an independent publicly traded company after being spun off from Tyco International.

Kyra Medical

KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Curve™ Spine Frame The KYRA Curve has a class-...

Service Drug Company

Service Drug Company is a Delta, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenocor

Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.